Long-term, low-dose erythromycin monotherapy for Mycobacterium avium complex lung disease: A propensity score analysis

International Journal of Antimicrobial Agents

Volumn 44, Issue 2, 2014, Pages 131-135

  Komiya, Kosaku ^a,b   Kurashima, Atsuyuki ^c,d   Ihi, Toshihiko ^e   Nagai, Hideaki ^d   Matsumoto, Nobuhiro ^f   Mizunoe, Shunji ^g   Ishii, Hiroshi ^a   Takahashi, Osamu ^h   Ohta, Ken ^d   Kudoh, Shoji ^c   Kadota, Jun Ichi ^a  

^a OITA UNIVERSITY   (Japan)

^b Tenshindo Hetsugi Hospital   (Japan)

^c Japan Anti Tuberculosis Association   (Japan)

^d TOKYO NATIONAL HOSPITAL   (Japan)

^e National Hospital Organization Miyazaki Higashi Hospital   (Japan)

^f UNIVERSITY OF MIYAZAKI   (Japan)

^g OITA PREFECTURAL HOSPITAL   (Japan)

^h St Luke's Life Science Institute   (Japan)

Author keywords

Erythromycin; Macrolide; Mycobacterium avium complex

Indexed keywords

CLARITHROMYCIN; ERYTHROMYCIN; ANTIINFECTIVE AGENT;

ADULT; AGED; ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; ATYPICAL MYCOBACTERIOSIS; CHRONIC DRUG ADMINISTRATION; CLINICAL EFFECTIVENESS; CONFERENCE PAPER; CONSERVATIVE TREATMENT; CONTROLLED STUDY; CROSS RESISTANCE; DISEASE EXACERBATION; DOSE RESPONSE; DRUG EFFICACY; FEMALE; HUMAN; LOW DRUG DOSE; LUNG INFECTION; LUNG INJURY; MAJOR CLINICAL STUDY; MALE; MINIMUM INHIBITORY CONCENTRATION; MONOTHERAPY; MYCOBACTERIUM AVIUM COMPLEX LUNG DISEASE; MYCOBACTERIUM INTRACELLULARE AVIUM; PRIORITY JOURNAL; PROPENSITY SCORE; RETROSPECTIVE STUDY; TREATMENT OUTCOME; COHORT ANALYSIS; DRUG EFFECTS; ISOLATION AND PURIFICATION; LUNG DISEASES; MICROBIOLOGY; MIDDLE AGED; MYCOBACTERIUM AVIUM COMPLEX; MYCOBACTERIUM AVIUM-INTRACELLULARE INFECTION; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; CLARITHROMYCIN; COHORT STUDIES; DRUG RESISTANCE, BACTERIAL; ERYTHROMYCIN; FEMALE; HUMANS; LUNG DISEASES; MALE; MIDDLE AGED; MYCOBACTERIUM AVIUM COMPLEX; MYCOBACTERIUM AVIUM-INTRACELLULARE INFECTION; PROPENSITY SCORE; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 84905571642     PISSN: 09248579     EISSN: 18727913     Source Type: Journal    
DOI: 10.1016/j.ijantimicag.2014.03.017     Document Type: Conference Paper

References (23)

1. D.E. Griffith, T. Aksamit, B.A. Brown-Elliott, A. Catanzaro, C. Daley, and F. Gordin et al. ATS Mycobacterial Diseases Subcommittee; American Thoracic Society; Infectious Disease Society of America. An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases Am J Respir Crit Care Med 175 2007 367 416 Erratum in: Am J Respir Crit Care Med 2007;175:744-5
2. R.M. Thomson, and W.W. Yew When and how to treat pulmonary non-tuberculous mycobacterial diseases Respirology 14 2009 12 26
3. M. Hayashi, N. Takayanagi, T. Kanauchi, Y. Miyahara, T. Yanagisawa, and Y. Sugita Prognostic factors of 634 HIV-negative patients with Mycobacterium avium complex lung disease Am J Respir Crit Care Med 185 2012 575 583
4. S. Kudoh, A. Azuma, M. Yamamoto, T. Izumi, and M. Ando Improvement of survival in patients with diffuse panbronchiolitis treated with low-dose erythromycin Am J Respir Crit Care Med 157 1998 1829 1832
5. J. Kadota, H. Mukae, T. Fujii, M. Seki, K. Tomono, and S. Kohno Clinical similarities and differences between human T-cell lymphotropic virus type 1-associated bronchiolitis and diffuse panbronchiolitis Chest 125 2004 1239 1247
6. D.F. Florescu, P.J. Murphy, and A.C. Kalil Effects of prolonged use of azithromycin in patients with cystic fibrosis: a meta-analysis Pulm Pharmacol Ther 22 2009 467 472
7. R.K. Albert, J. Connett, W.C. Bailey, R. Casaburi, J.A. Cooper Jr., and G.J. Criner et al. Azithromycin for prevention of exacerbations of COPD N Engl J Med 365 2011 689 698
8. J. Altenburg, C.S. de Graaff, Y. Stienstra, J.H. Sloos, E.H. van Haren, and R.J. Koppers et al. Effect of azithromycin maintenance treatment on infectious exacerbations among patients with non-cystic fibrosis bronchiectasis: the BAT randomized controlled trial JAMA 309 2013 1251 1259
9. D.J. Serisier, M.L. Martin, M.A. McGuckin, R. Lourie, A.C. Chen, and B. Brain et al. Effect of long-term, low-dose erythromycin on pulmonary exacerbations among patients with non-cystic fibrosis bronchiectasis: the BLESS randomized controlled trial JAMA 309 2013 1260 1267
10. E.J. Cameron, C. McSharry, R. Chaudhuri, S. Farrow, and N.C. Thomson Long-term macrolide treatment of chronic inflammatory airway diseases: risks, benefits and future developments Clin Exp Allergy 42 2012 1302 1312
11. A. Canu, B. Malbruny, M. Coquemont, T.A. Davies, P.C. Appelbaum, and R. Leclercq Diversity of ribosomal mutations conferring resistance to macrolides, clindamycin, streptogramin, and telithromycin in Streptococcus pneumoniae Antimicrob Agents Chemother 46 2002 125 131
12. M. Matsuoka, M. Narita, N. Okazaki, H. Ohya, T. Yamazaki, and K. Ouchi et al. Characterization and molecular analysis of macrolide-resistant Mycoplasma pneumoniae clinical isolates obtained in Japan Antimicrob Agents Chemother 48 2004 4624 4630
13. G. Alvarez-Uria Lung disease caused by nontuberculous mycobacteria Curr Opin Pulm Med 16 2010 251 256
14. K.L. Winthrop, E. McNelley, B. Kendall, A. Marshall-Olson, C. Morris, and M. Cassidy et al. Pulmonary nontuberculous mycobacterial disease prevalence and clinical features: an emerging public health disease Am J Respir Crit Care Med 182 2010 977 982
15. W.J. Koh, B.H. Jeong, K. Jeon, N.Y. Lee, K.S. Lee, and S.Y. Woo et al. Clinical significance of the differentiation between Mycobacterium avium and Mycobacterium intracellulare in M. avium complex lung disease Chest 142 2012 1482 1488
16. T. Kikuchi, A. Watanabe, K. Gomi, T. Sakakibara, K. Nishimori, and H. Daito et al. Association between mycobacterial genotypes and disease progression in Mycobacterium avium pulmonary infection Thorax 64 2009 901 907
17. P.B. Fernandes, D.J. Hardy, D. McDaniel, C.W. Hanson, and R.N. Swanson In vitro and in vivo activities of clarithromycin against Mycobacterium avium Antimicrob Agents Chemother 33 1989 1531 1534
18. S. Naik, and R. Ruck In vitro activities of several new macrolide antibiotics against Mycobacterium avium complex Antimicrob Agents Chemother 33 1989 1614 1616
19. W.J. Koh, B.H. Jeong, K. Jeon, S.Y. Lee, and S.J. Shin Therapeutic drug monitoring in the treatment of Mycobacterium avium complex lung disease Am J Respir Crit Care Med 186 2012 797 802
20. H. Nagai, H. Shishido, R. Yoneda, E. Yamaguchi, A. Tamura, and A. Kurashima Long-term low-dose administration of erythromycin to patients with diffuse panbronchiolitis Respiration 58 1991 145 149
21. S. Kudoh Applying lessons learned in the treatment of diffuse panbronchiolitis to other chronic inflammatory diseases Am J Med 117 Suppl. 9A 2004 12S 19S
22. B. Dautzenberg, D. Piperno, P. Diot, C. Truffot-Pernot, and J.P. Chauvin Clarithromycin in the treatment of Mycobacterium avium lung infections in patients without AIDS. Clarithromycin Study Group of France Chest 107 1995 1035 1040
23. D.E. Griffith, B.A. Brown-Elliott, B. Langsjoen, Y. Zhang, X. Pan, and W. Girard et al. Clinical and molecular analysis of macrolide resistance in Mycobacterium avium complex lung disease Am J Respir Crit Care Med 174 2006 928 934